Form 4: Rocket Pharma CEO's RSU Tax Withholding

Rocket Pharmaceuticals CEO Gaurav Shah reported a disposition of 2,234 common shares for tax withholding related to Restricted Stock Unit vesting.

Summary

• Gaurav Shah, CEO and Director of Rocket Pharmaceuticals, Inc. (RCKT), reported a transaction on August 18, 2025.
• 2,234 shares of common stock were disposed of at a price of $3.05 per share.
• This disposition was due to the company withholding shares to cover tax obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Shah directly beneficially owns 784,572 shares of common stock.
• Indirect beneficial ownership includes 207,897 shares held by his spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction for tax withholding on RSU vesting, which is an expected part of executive compensation and indicates continued alignment of management with shareholder interests, despite a minor reduction in direct share count.

Positives

• The disposition of shares was for tax withholding purposes related to the vesting of Restricted Stock Units (RSUs), indicating compensation and continued alignment of management interests with shareholders.
• Gaurav Shah retains a significant direct beneficial ownership of 784,572 common shares, plus substantial indirect holdings.

Negatives

• A reduction of 2,234 shares in direct beneficial ownership, although for tax purposes.

Future Outlook

NA

Industry Context

This is a routine insider transaction for tax purposes related to equity compensation, common across all industries for executives receiving Restricted Stock Units (RSUs). It does not reflect specific industry trends or competitive positioning.

Comparison to Industry Standards

• This type of transaction (shares withheld for tax on RSU vesting) is a standard practice for equity compensation across publicly traded companies.
• It aligns with typical executive compensation structures where RSUs vest over time, and a portion is automatically sold or withheld to cover statutory tax obligations.
• No specific comparable companies or projects are relevant as this is a procedural compensation event.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine tax-related transaction and the CEO retains significant ownership.
• Positive for the executive (Gaurav Shah) as it represents the vesting of equity compensation.

Key Dates

Keywords

Rocket Pharmaceuticals, RCKT, Gaurav Shah, Form 4, SEC filing, insider transaction, beneficial ownership, Restricted Stock Units, RSU, tax withholding, CEO, director